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Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and
TRAIL-R/Apo2-mediated cell death but not gene induction
Harald Wajant, Franz-Josef Johannes, Elvira Haas, Katrin Siemienski, Ralph
Schwenzer, Gisela Schubert, Tilo Weiss, Matthias Grell and Peter Scheurich
Fas/Apo1 and other cytotoxic receptors of the tumor
necrosis factor receptor (TNFR) family contain a
cytoplasmic death domain (DD) [1–11] that activates
the apoptotic process by interacting with the DD-
containing adaptor proteins TNFR-associated DD
protein (TRADD) [12,13] and Fas-associated DD protein
(FADD/MORT1) [14,15], leading to the activation of
cysteine proteases of the caspase family [16].
Stimulation of Fas/Apo1 leads to the formation of a
receptor-bound death-inducing signaling complex
(DISC), consisting of FADD and two different forms of
caspase-8 [17–19]. Transient expression of a dominant-
negative mutant of FADD impairs TNFR60-mediated
and Fas/Apo1-mediated apoptosis [13,20], but has no
effect on TNF-related apoptosis-inducing ligand
(TRAIL/Apo2L)-induced cell death [7–10,21]. To study
the function of FADD in DD-receptor signaling in more
detail, we established HeLa cells that stably expressed
a green fluorescent protein (GFP)-tagged dominant-
negative mutant of FADD, GFP–∆FADD. Interestingly,
expression of this mutant inhibited cell death induced
by TNFR60, Fas/Apo1 and TRAIL-R/Apo2. In addition,
GFP–∆FADD did not interfere with TNF-mediated gene
induction or with activation of NF-κB or Jun N-terminal
kinase (JNK), demonstrating that FADD is part of the
TNFR60-initiated apoptotic pathway but does not play a
role in TNFR60-mediated gene induction. Fas/Apo1-
mediated activation of JNK was unaffected by the
expression of GFP–∆FADD, suggesting that in
Fas/Apo1 signaling the apoptotic pathway and the
activation of JNK diverge at a level proximal to the
receptor, upstream of or parallel to FADD.
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Results and discussion
To investigate the role of FADD in DD-receptor signal-
ing, we introduced a plasmid encoding a fusion protein in
which the amino-terminal death effector domain of FADD
was replaced by GFP, into HeLa cells. The use of GFP
allows easy and reliable detection of the fusion protein but
also facilitates the generation of HeLa populations express-
ing high levels of GFP–∆FADD by rounds of fluores-
cence-activated cell sorting (FACS). Analysis by FACS of
pools of pcDNA3.1-GFP–∆FADD transfectants revealed
that 10–30% of these cells expressed the fusion protein,
with expression levels varying over 3–4 orders of magni-
tude (data not shown). HeLa populations expressing high
levels of GFP–∆FADD were obtained after three cycles of
cell sorting (Figure 1a,b). As shown in Figure 2a,b, cell
death mediated by TNFR60 and TRAIL-R/Apo2 was par-
tially blocked in cells expressing intermediate levels of
GFP–∆FADD, GFP–∆FADD(low), and was completely
inhibited in cells expressing high levels of GFP–∆FADD,
whereas control cells expressing GFP alone remained sen-
sitive. As HeLa cells express only a limited amount of the
Fas/Apo1 receptor, we introduced the GFP–∆FADD
expression construct into HeLa cells that had already been
transfected with the Fas/Apo1 receptor (HeLa-Fas) and
were therefore susceptible to Fas/Apo1-mediated cell
death. Fas/Apo1-mediated cell death was completely pre-
vented in cells expressing GFP–∆FADD (Figure 2c).
Moreover, the sensitivity of all GFP–∆FADD transfectants
against other apoptosis-inducing agents such as daunoru-
bicin or ceramide was unaffected (data not shown), empha-
sizing the specificity of GFP–∆FADD action. 
These results suggest that in HeLa cells FADD repre-
sents an essential part of the apoptotic pathways initiated
by the TNFR60, TRAIL-R/Apo2 and Fas/Apo1 DD
receptors, or that GFP–∆FADD interferes with other DD
signaling proteins involved in these pathways. Transient
expression studies in HeLa-S3 [9,10,21] and MCF7 [7,9]
cells, however, have suggested that the TRAIL/Apo2L
couples to the caspase cascade via a FADD-independent
pathway. FADD-independent pathways that connect DD-
receptor signaling complexes with the caspase cascade
have also been suggested by the cloning of the adaptor
molecule RAIDD/CRADD [22,23], which comprises a
carboxy-terminal DD that binds to the DD of the Fas- or
TNFR-interacting protein, RIP, and an amino-terminal
domain homologous to the predomain of caspase-2
[22,23]. Such a FADD-independent pathway might not
play a major role in HeLa cells, as RIP mRNA is barely
detectable in these cells by RNAse protection assay (data
not shown). Recent data have demonstrated the existence
of at least two distinct DD receptors specific for
TRAIL/Apo2L, termed DR4 (death receptor 4) [7] and
DR5/TRICK2 (TRAIL receptor inducer of cell killing 2)
[9–11]. Transient expression studies have suggested that
FADD does not bind directly to these receptors [9,10].
Similarly, we were unable to detect GFP–∆FADD in
TRAIL/Apo2L immunoprecipitates (data not shown). In
accordance with these data, expression of ∆FADD had no
effect or only minor effects on cell death induced by over-
expression of DR4 [7] and DR5 [9,10]. Results of these
transient assays are not, however, directly comparable to
the data obtained here using stable GFP–∆FADD trans-
fectants, as expression following transient transfection is
extremely heterogeneous (data not shown).
Hsu et al. [12] have recently shown that the TNFR60-
induced pathways leading to apoptosis and activation of
NF-κB bifurcate at the level of TRADD. Whereas the
amino terminus of TRADD mediates binding to TRAF2
(TNFR-associated factor) [13], which in turn activates
NF-κB by stimulating the phosphorylation of IκBα medi-
ated by NIK (NF-κB-inducing kinase) [24], the carboxy-
terminal DD of TRADD mediates FADD binding and
subsequent activation of the caspase cascade [13]. As
thereby expected, GFP–∆FADD expression had no effect
on NF-κB or JNK activation by TNF (Figure 3a,b). We
have recently shown that TNF upregulates cIAP2
(inhibitor of apoptosis) and TRAF1 mRNA in HeLa cells
(T.W. and H.W., unpublished observations). As shown in
Figure 3c, there is no difference in the TNF-mediated
induction of these genes in the HeLa-GFP–∆FADD cells,
compared to the HeLa-GFP cells. This result is consistent
with a bifurcation of the pathways that induce apoptosis
(caspase cascade) and gene activation (via NF-κB, JNK) at
the level of TRADD. In contrast with TNFR60 signaling,
engagement of Fas/Apo1 results in the activation of JNK
but not NF-κB (data not shown). The activation of JNK
by Fas/Apo1 was also unaffected in HeLa-Fas-
GFP–∆FADD transfectants (Figure 3d). This finding is in
good accordance with experiments demonstrating that
Daxx, a recently identified Fas/Apo1-binding protein,
activates JNK independently from FADD and potentiates
the apoptotic pathway initiated by Fas/Apo1 [25]. Because
Fas/Apo1-mediated activation of JNK is significantly
increased in HeLa-Fas-GFP–∆FADD cells compared
with control cells, cross-talk might occur between the
FADD-dependent and Daxx-dependent signaling path-
ways initiated by Fas/Apo1.
Materials and methods
Generation of pcDNA3.1-GFP–∆FADD
Full-length EGFP, a red-shifted variant of wild-type GFP, was amplified
by PCR from pEGFP-N1 (Clontech) using oligonucleotides designed
to amplify the complete coding region and add BglII and HindIII sites.
These sites were used for subsequent cloning into pcDNA3.1∆FADD.
The ∆FADD fusion protein contains amino acids 80–208 of FADD with
the death effector domain of FADD being replaced by EGFP.
Cells, DNA transfection, cell sorting and cytotoxicity assay
HeLa cell lines were grown under standard conditions. Lipid-vesicle-
mediated transfections were carried out using Pfx-2 (Invitrogen)
according to the manufacturer’s instructions. Transfected cells were
selected in culture medium containing 600 µg/ml G418 (Gibco BRL).
At 20 days post transfection, individual drug-resistant colonies were
pooled, expanded and enriched for highly expressing cells by three
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Figure 1
Analysis of GFP and GFP–∆FADD expression. HeLa cells were stably
transfected with plasmids encoding GFP or GFP–∆FADD, and the
transfected cells were sorted for subpopulations that expressed high
levels of the respective protein. (a) FACS analysis of the expression of
GFP and GFP–∆FADD in HeLa transfectants. HeLa-
GFP–∆FADD(low) cells express intermediate levels of the fusion
protein and HeLa-GFP–∆FADD(high) cells express high levels. HeLa-
Fas-GFP–∆FADD cells express the Fas/Apo1 receptor and the GFP
fusion protein, and HeLa-GFP cells express GFP alone. (b)
Examination of each cell line in (a) by fluorescence microscopy.
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GFP–∆FADD prevents cell death mediated by TNF, Fas/Apo1 and
TRAIL/Apo2L. HeLa-GFP and HeLa-GFP–∆FADD (low and high
expressing cells), as well as HeLa-Fas-GFP–∆FADD and HeLa-Fas
cells were plated in 96-well microtiter plates at a density of
1.5 × 104 cells per well, in triplicate, overnight at 37°C. The cells
were then treated for 24 h with various concentrations of (a) TNF,
(b) a complex of TRAIL/Apo2L tagged with the FLAG epitope and
anti-FLAG M2 antibody and (c) anti-Apo1, in the presence of
2.5 µg/ml cycloheximide. Viable cells were quantified upon staining
with crystal violet.
Figure 3
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GFP–∆FADD does not interfere with stimulatory effects mediated by
TNF and Fas/Apo1. (a) Electrophoretic mobility shift assay (EMSA) of
NF-κB activation in HeLa-GFP and HeLa-GFP–∆FADD cells. Cells
(3 × 106) were treated with TNF at the indicated concentrations. After
30 min, nuclear extracts were prepared and analyzed with a 32P-
labeled oligonucleotide probe containing an NF-κB binding site. A
control reaction was performed with a 100-fold excess of unlabeled
NF-κB-specific competitor oligonucleotide. (b) Activation of JNK by
TNF in HeLa-GFP and HeLa-GFP–∆FADD cells. Cells were stimulated
for 30 min with TNF, and JNK activation was measured by an
immunocomplex kinase assay using GST–Jun(amino acids 1–79) as
the substrate. (c) Analysis by RNase protection assay of HeLa-GFP
and HeLa-GFP–∆FADD cells for steady-state levels of various
members of the TRAF and IAP families. Cells were treated with TNF at
the indicated concentrations. RNAs were isolated and analyzed with
the hApo-5 Multi-Probe template set to detect xIAP, TRAF1, TRAF2,
CART, NAIP, cIAP2, cIAP1, TRPM2 and TRAF3 mRNAs. (d)
Activation of JNK by Fas/Apo1-stimulation in HeLa-Fas-GFP–∆FADD
and HeLa-Fas cells. Cells were stimulated for 4 h with anti-Apo1 and
JNK activity was measured as described in (b).
cycles of cell sorting using a FACStarplus (Becton and Dickinsion).
Cytokine-induced apoptosis was measured by determination of viability
using crystal-violet staining essentially as described [26].
EMSA analysis of NF-κB and JNK activation
Electrophoretic mobility shift assays were performed as previously
described [26]. Assays of JNK activity were performed after immuno-
precipitation of JNK1 using a rabbit antiserum (Santa Cruz Biotechnol-
ogy). GST–Jun was used as the substrate in an in vitro kinase assay
essentially as described [27].
RNase protection assays
Cells (5–10 × 106) were treated with the reagents indicated in Figure 3
and RNA was subsequently isolated with the RNeasy RNA purification
kit (Qiagen) according to the manufacturer’s recommendations. The
RNA samples were analyzed for the presence of transcripts of xIAP,
TRAF1, TRAF2, CART, NAIP, cIAP2, cIAP1, TRPM2 and TRAF3 with
the hApo-5 Multi-Probe template set (PharMingen). L32 and GAPDH
were included as internal controls. RNase protection assays were per-
formed with the RiboQuant Multi-Probe RNase Protection Assay
System (PharMingen) according to the manufacturer’s recommenda-
tions. Protected transcripts were separated by denaturing polyacry-
lamide gels and quantified using a phosphorimager.
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